|
Synonyms: ch38SB19 | hu38SB19 | isatuximab-irfc | SAR-650984 | SAR650984 | Sarclisa®
isatuximab is an approved drug (EMA & FDA (2020))
Compound class:
Antibody
Comment: Isatuximab is an anti-CD38 monoclonal antibody that was designed for anti-tumour potential [2].
A patent search identifies the peptide sequences of the light and heavy chain variable regions of isatuximab as SEQ ID NO: 22 and SEQ ID NO: 21 from patent US 8877899 B2 [6] (and equates to Ref mAB5 in the patent document). This patent further refers these sequences to WO2008047242 A8, but neither this or any associated patent (eg US20110262454 A1) provide peptide sequences to allow identification of isatuximab therein. The most likely patent defined embodiment being isatuximab is hu38SB19 [4]. 
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA et al.. (2019)
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet, 394 (10214): 2096-2107. [PMID:31735560] |
|
2. Deckert J, Wetzel MC, Bartle LM, Skaletskaya A, Goldmacher VS, Vallée F, Zhou-Liu Q, Ferrari P, Pouzieux S, Lahoute C et al.. (2014)
SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res, 20 (17): 4574-83. [PMID:24987056] |
|
3. FDA.
SARCLISA; Biologic License Application (BLA) 761113. Accessed on 03/03/2020. Modified on 03/03/2020. Drugs@FDA: FDA-Approved Drugs, https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=761113 |
|
4. Park PU, Bartle L, Skaletskaya A, Golmakher V, Tavares D, Deckert J, Milol V, Blanc V. (2011)
Novel anti-cd38 antibodies for the treatment of cancer. Patent number: US20110262454 A1. Assignee: Sanofi-Aventis. Priority date: 20/08/2015. Publication date: 27/10/2011. |
|
5. Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML, Corzo K, Anderson KC. (2018)
Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol, 14 (11): 1035-1047. [PMID:29268619] |
|
6. Rojkjaer L, Boxhammer R, Endell J, Winderlich M, Samuelsson C. (2014)
Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL. Patent number: US8877899 B2. Assignee: Morphosys Ag.. Priority date: 27/09/2010. Publication date: 04/11/2014. |
